Literature DB >> 23880974

Dacryoendoscopic findings in the lacrimal passage in failed dacryocystorhinostomy.

Yasuhiro Takahashi1, Yasuhisa Nakamura, Hirohiko Kakizaki.   

Abstract

PURPOSE: To examine the appearance of the lacrimal passage using dacryoendoscopy in failed dacryocystorhinostomies, examining the relationship between the remnant lacrimal sac mucosa and the obstruction tissue, and to detect canalicular obstruction.
METHODS: Twenty failed dacryocystorhinostomies (4 right and 16 left) in 19 Japanese patients (8 males and 11 females) aged 36 to 81 years (average, 69.5 years) were reviewed. Dacryoendoscopy was used to examine the lacrimal passage of the failed dacryocystorhinostomies.
RESULTS: An occluded space was found with no adhesion between the remnant lacrimal sac mucosa and the fibrous obstruction tissue in every failed dacryocystorhinostomy. None of the lacrimal canaliculi or the common internal ostia was obstructed.
CONCLUSIONS: A space without adhesion between the remnant lacrimal sac mucosa and the obstruction tissue was visualized in all the failed dacryocystorhinostomies. No canalicular stenosis was seen, including the common internal ostium, in this cases. Based on these results, endoscopic revision for failed dacryocystorhinostomies is a safe procedure, performed without orbital fat prolapse.

Entities:  

Mesh:

Year:  2013        PMID: 23880974     DOI: 10.1097/IOP.0b013e31829a72f9

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  2 in total

1.  Potential candidate cells for constructing tissue-engineered lacrimal duct epithelium: a histological and cytological study in rabbits.

Authors:  Chen Xie; Xiu-yi Li; Hong-guang Cui
Journal:  J Zhejiang Univ Sci B       Date:  2015-11       Impact factor: 3.066

2.  Endoscopic dacryocystorhinostomy with an otologic T-type ventilation tube in repeated revision cases.

Authors:  Sihai Wu; Ting Xu; Bin Fan; Dajiang Xiao
Journal:  BMC Ophthalmol       Date:  2017-08-07       Impact factor: 2.209

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.